|
19 Mar 2019 |
NeuroVive Enrolls First Subject in its KL1333 Phase Ia/b Clinical Study
|
|
19 Mar 2019 |
Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
|
|
19 Mar 2019 |
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
|
|
19 Mar 2019 |
Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitis
|
|
19 Mar 2019 |
AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention
|
|
19 Mar 2019 |
Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion
|
|
19 Mar 2019 |
Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy
|
|
19 Mar 2019 |
Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting
|
|
19 Mar 2019 |
Daiichi Sankyo Presents Positive Results of the First Randomized, Controlled Trial of Uninterrupted Oral, Once-daily Lixiana® (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation
|
|
17 Mar 2019 |
Enigma Biomedical Group Signs License Agreement with Merck for Novel MK-6884 Imaging Agent
|
|
15 Mar 2019 |
Lexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study, a Phase 2a Clinical Study of Telotristat Ethyl in Biliary Tract Cancer
|
|
14 Mar 2019 |
Phase III clinical trial with Bayer’s Nifurtimox demonstrates safety and efficacy of new formulation to treat children with Chagas disease
|
|
13 Mar 2019 |
Adare Pharmaceuticals Announces Achievement of the Primary End-Point in Phase IIb Study (FLUTE™) for APT-1011 in Patients with Eosinophilic Esophagitis
|
|
13 Mar 2019 |
Advicenne Announces Submission of European Marketing Authorization Application (MAA) for ADV7103 as Treatment for Distal Renal Tubular Acidosis (dRTA)
|
|
13 Mar 2019 |
Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
|
|
13 Mar 2019 |
Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer
|
|
11 Mar 2019 |
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
|
|
11 Mar 2019 |
Navitor Pharmaceuticals Announces Peer-Reviewed Publication Detailing the Discovery and Development of NV-5138
|
|
11 Mar 2019 |
Tenax Therapeutics Enrolls First Patient for Phase 2 Pulmonary Hypertension Clinical Trial
|
|
11 Mar 2019 |
Tricida Announces Publication of Positive TRC101 Pivotal Trial Results in The Lancet
|
|
11 Mar 2019 |
Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
|
|
10 Mar 2019 |
Forendo Pharma Successfully Completes Phase 1a Clinical Trial of FOR-6219 for the Treatment of Endometriosis
|
|
09 Mar 2019 |
Spruce Biosciences Announces Presentation of Positive Topline Data from Phase 2 Study of Tildacerfont (SPR001) in Congenital Adrenal Hyperplasia at the 2019 Annual Meeting of the Endocrine Society (ENDO)
|
|
09 Mar 2019 |
ViiV Healthcare Presents Positive, 48-Week Data from Two Pivotal Phase III Studies Showing Long-Acting, Injectable Two-Drug Regimen of Cabotegravir and Rilpivirine Has Similar Efficacy to Daily, Three-Drug Oral Treatment in Adults Living with HIV-1 Infect
|
|
09 Mar 2019 |
Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies
|
